IRICoR | An Innovative Approach to Drug Discovery

ELIZABETH DOUVILLE APPOINTED PRESIDENT AND CHIEF EXECUTIVE OFFICER OF IRICoR

Ipsen, UdeM and IRICoR broaden existing oncology partnership, with an exclusive license agreement and two new discovery-stage programs

New Strategic Investment of IRICoR in RejuvenRx Spin-off

Dre Gwenaëlle Gavory joins the IRICoR team

Intellectual property management: a formidable marketing lever for anticancer therapies

New VP – Scientific Operations at IRICoR

IRICoR welcomes the appointment of Nadine Beauger as a member of the Board of Directors of Canada’s Stem Cell Network

IRICoR will attend the LES 2022 Annual Meeting

Ms Nioucha Rodrigue joins the IRICoR team

News

IRICoR @iricor_ ·

27 Feb

Nous sommes heureux d'annoncer la nomination d' @ElizDouville, à titre de Présidente – Directrice générale d’IRICoR.

Femme d’affaires avisée, Elizabeth saura accompagner et insuffler sa vision pour amener IRICoR encore plus loin et assoir sa crédibilité

https://bit.ly/3Zk6onG

IRICoR @iricor_ ·

15 Feb

“The signing of the exclusive license agreement and the launch of a new collaboration for the discovery of new compounds against high-value oncology targets represent a natural expansion of our strategic partnership with @IpsenGroup" Claude Larose-VP Business Development @IRICoR_

IRICoR @iricor_ ·

27 Jan

IRICoR est fier d'annoncer un investissement stratégique dans RejuvenRx, spin-off co-fondée avec ExCellThera. RejuvenRx développe de nouvelles thérapies moléculaires dans le but de vaincre le cancer et maîtriser le vieillissement.
https://bit.ly/3wzCiQV